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Abstract
Background: Adynamia in fibromyalgia (FM) may be an expression of a functional deficit of the
hypothalamic-pituitary-adrenal axis and be associated with below-normal levels of urinary cortisol.
Our aim was to demonstrate that urinary cortisol was lower in patients with FM than in healthy
subjects.
Findings: We measured urinary cortisol levels for a sample of 47 women aged 29 to 64 years
(mean age 53 years), diagnosed with FM 2–3 years previously, and compared the results with those
for a control sample of 58 healthy women of a similar age. Samples of 24-hour urine were
appropriately collected and levels of urinary cortisol were measured using the fluorescence
polarization immunoassay method. The mean cortisol value for the women with FM was 65.40 ±
27.10 μg/L, significantly lower than the mean cortisol level for the control group, at 90.83 ± 38.17
μg/L (p < 0.001).
Conclusion: Our study confirms that women with FM have significantly lower urinary cortisol
levels than healthy women.
Background
Fibromyalgia (FM) is an illness of unknown etiology that
is characterized by chronic pain that patients locate in the
musculoskeletal system [1]. Tending to develop from
around the age of 45–55 years, mainly in women, it affects
between 2% and 4% of the world population. In Spain,
maximum prevalence (4.9%) occurs among adults aged
40–49 years old [1].
FM is influenced by factors such as stress, illness, and pain
in some – but not all patients – as well as by certain neu-
rotransmitter and neuroendocrine changes, including
reduced biogenic amine levels, increased excitatory neuro-
transmitter concentrations and alterations in the hypoth-
alamic-pituitary-adrenal axis and in autonomic nervous
system activity [2-4]. Studies of cortisol levels and the
hypothalamic-pituitary-adrenal axis are motivated by the
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high prevalence of stress and depression reported for
patients with FM.
Abnormalities are not generally detected in laboratory
tests unless the patient is being tested for another illness.
Factors that contribute to the development or perpetua-
tion of FM include endocrine alterations [5]. Studies have
demonstrated a latent decrease in the level of certain hor-
mones, such as the growth hormone, prolactin, adreno-
corticotrophic hormone and cortisol [6,7].
Growth hormone and cortisol deficiencies lead to multi-
functional disorders in response to stress, with the
decrease in adrenocortical feedback possibly explaining
the intense and permanent exhaustion experienced by
patients with FM. Adrenal production of cortisol is also
found to be lower in patients with FM, and the cortisol
deficit, peripheral in origin, combines with hypotha-
lamic-pituitary-adrenal axis dysfunctioning; the same
happens with the growth hormone and insulin-like
growth factor 1 [8,9]. Low cortisol levels cause reduced
adrenalin production, leading to defective organic
response to stress. It has also been demonstrated that
patients with FM show greater resistance to the produc-
tion of cortisol. A lack of cortisol can generate reduced tol-
erance to exertion and greater muscular fatigue and is also
associated with mood swings, sleep disorders and depres-
sion [10,11].
Some authors suggest that the combined reduction in cor-
tisol, prolactin and GH levels could be a good biochemi-
cal marker of FM [12].
No specific laboratory test exists for FM. However, it is
important to study the existence of other clinical manifes-
tations that could produce similar symptoms or compli-
cate the course of the FM. Recommended tests include a
complete blood count, erythrocyte sedimentation rate,
creatine kinase, C-reactive protein, thyrotropin and pro-
tein profile [1,13]. Most studies to date have fundamen-
tally focused on studying varying cortisol levels in saliva
and blood, but have failed to arrive at conclusions as to
why variations occur in patients with FM. Reduced levels
of cortisol in the blood of patients with FM have not been
reported; on the contrary, in some cases, considerable
increases have been reported [14].
Given that determining cortisol is not relevant from a clin-
ical point of view and also that urinary cortisol is a reflec-
tion of the free fraction of the hormone, urinary cortisol is
more representative of organic secretion than plasma cor-
tisol.
We conducted a study of urinary cortisol levels for a group
of women diagnosed with long-standing FM (2–3 years)
and compared these levels with those for a group of
healthy women of a similar age. The aim of this study was
to verify whether the urinary concentration of cortisol in
the group of patients with FM was significantly lower with
respect to the control group and so explain the adynamia
of patients with FM.
Methods
The study design and protocol were reviewed and
approved by the Ethics Committee of the Hospital Uni-
versitario Miguel Servet in Zaragoza, Spain, in accordance
with the Declaration of Helsinki and the Nuremberg
Code. All the patients in the study granted their informed
consent.
A sample group of 53 women was randomly selected from
among members of the Aragonese Fibromyalgic and
Chronic Fatigue Association (ASAFA). These women had
been diagnosed in accordance with American College of
Rheumatology diagnostic criteria for FM. Exclusion crite-
ria were pregnancy, hypothyroidism and the use of corti-
costeroids and anti-depressive drugs in the 6 months prior
to sampling, leading to the exclusion of 6 patients from
the initial sample of 53 women study. The patients, aged
between 29 and 64 years (mean, 53 years) and with a nor-
mal body mass index (that is, 18.50 to 24.99 kg/m2), had
long-standing FM (2–3 years). In order to establish nor-
mality values for urinary cortisol for comparison with the
values obtained for the patients with FM, urine samples
were also taken for 58 healthy women in a very similar age
range (30–65 years, mean 45.5), who acted as a control
group.
Urinary cortisol was quantitatively determined by means
of a fluorescence polarization immunoassay (FPIA) run
on an AxSYM autoanalyzer (Abbott Laboratories). The
analytical characteristics of the method were precision
and accuracy of ≤ 5%, sensitivity of 95%, coefficient of
variation of < 5% and a detection limit of ≤ 1 μg/mL. The
sample was an aliquot of 24-hour urine, appropriately
collected and delivered immediately and directly to the
laboratory.
Samples that could not be processed in the first 24 hours
were kept cool; if processing was postponed for more than
4 days, the samples were frozen at -20°C.
Statistical analyses were performed using SPSS for Win-
dows, Version 13.0. The Kolmogorov-Smirnov test was
used to determine that distributions for the FM and con-
trol groups were normal for the studied variables, namely,
μg urinary cortisol/L, μg cortisol/24-hour urine (bearing
in mind diuresis) and the cortisol/creatinine ratio (to
evaluate whether urine sampling had been performed cor-
rectly).BMC Research Notes 2008, 1:134 http://www.biomedcentral.com/1756-0500/1/134
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For normal distributions, the t test for independent sam-
ples was applied; in other words, the means and variances
for the two independent groups were compared. For non-
normal distributions, we used the non-parametric Mann-
Whitney U test, with the corresponding calculation of sig-
nificance levels.
Results
The mean 24-hour urinary cortisol value for the control
group was 90.83 ± 38.17 μg/L, compared to a value of
65.40 ± 27.10 μg/L for the patients with FM (p < 0.001).
The cortisol value expressed in μg/24 hours was 144.22 ±
64.77 for the control group and 137.00 ± 201.05 for the
FM group (p < 0.5). The cortisol/creatinine ratio was
116.82 ± 62.86 for the control group and 97.50 ± 38.42
for the FM group (p < 0.5).
The reference range for 24-hour urinary cortisol showed
wide variation. In all probability, the absence of appropri-
ate separation (using high-performance liquid chroma-
tography) results in a false signal due to cross-reactivity
with reduced cortisol metabolites, which are present in
high concentrations in urine.
The values for 24-hour urinary cortisol depended on urine
collection quality – a key factor in terms of obtaining reli-
able results, given that individual variations and meta-
bolic or pharmacological interference may alter
metabolism. Most of the patients with FM presented
lower levels of urinary cortisol than normal, an observa-
tion that corroborates other studies [5,10,14] indicating
lower adrenal production of cortisol in patients with FM.
Previous studies showed urinary free cortisol levels in
patients with FM to be within the normal range [14-16] or
significantly below the lower normal limit [9,17].
The 24-hour urinary cortisol value depends on the analyt-
ical selectivity of the antiserum used for the immu-
noassay. The fact that antiserum cross-reactivity may
significantly influence the respective cutoff values appears
to be the major drawback of the proposed method.
The cortisol deficit found in the patients in our study
could partly account for their FM and be associated with
adynamia, mood swings, sleep disorders, depression and
increased muscular pain following exercise [18]. FM does
not improve in response to treatment with corticosteroids
[19].
With regard to using 24-hour urinary cortisol levels as a
possible biochemical marker for FM, treatment with corti-
costeroids or anti-depressants should be taken into
account, given that such drugs tend to raise cortisol levels.
Conclusion
Information on 24-hour urine cortisol levels does not
constitute useful information in itself, but may be valua-
ble when combined with other clinical tests normally per-
formed to diagnose FM. Although a dysfunctional
hypothalamic-pituitary-adrenal axis can lead to decreased
sensitivity and resiliency in the stress system, it does not
necessarily affect baseline cortisol levels, so 24-hour uri-
nary cortisol levels alone cannot be used to evaluate FM.
Urinary cortisol is a potentially useful biochemical marker
in terms of evaluating adynamia in FM, along with insu-
lin-like growth factor 1, substance P and the terminal tel-
opeptides [20]. Nonetheless, studies based on larger
samples are necessary in order to corroborate these con-
clusions.
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